ABT-751 Radiosensitization for Brain Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain tumors, including surgery, radiotherapy, and traditional chemotherapeutic agents, are limited by the blood-brain barrier and cause severe toxic side effects, necessitating a need for more effective and less toxic therapies.
Innovation Solution
Administering ABT-751, a chemotherapeutic agent that selectively increases the radiation sensitivity of dividing tumor cells in the brain without harming surrounding tissue, combined with ionizing radiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used to treat brain tumors, then tumor cells are killed through cytotoxic mechanisms, but severe toxic side effects occur due to non-selective cytotoxicity
Solution Approach 1:
The patent applies local quality by making the chemotherapeutic agent's action selective: ABT-751 preferentially accumulates in and acts on tumor cells rather than normal cells. This is achieved through the compound's ability to cross the blood-brain barrier and its selective uptake or retention in tumor tissue, creating a localized high concentration at the tumor site while maintaining lower concentrations in healthy tissues, thereby resolving the contradiction between effective tumor cell killing and reduction of toxic side effects
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure and pharmacokinetic properties of the chemotherapeutic agent to achieve selective tumor targeting. ABT-751 has altered molecular characteristics that enable it to cross the blood-brain barrier and accumulate in tumor cells, changing the distribution parameter from uniform (as with traditional agents) to selective (high in tumor, low in normal tissue), thus improving the therapeutic index by separating efficacy from toxicity
2Reliability
If adequate delivery of chemotherapeutic agents to brain tumors is attempted, then treatment efficacy may be improved, but the blood-brain barrier hinders agent delivery
Solution Approach 1:
The patent resolves the blood-brain barrier delivery problem through parameter changes in the chemotherapeutic agent's molecular properties. ABT-751 possesses specific physicochemical characteristics (such as lipophilicity, molecular size, and structural features) that enable it to traverse the blood-brain barrier, transforming the delivery scenario from blocked to permeable, thereby achieving effective tumor concentrations without requiring complex delivery systems
Solution Approach 2:
The patent implicitly uses the chemotherapeutic agent ABT-751 itself as an intermediary that facilitates its own delivery across the blood-brain barrier. The compound's molecular structure acts as a mediator that interacts with the barrier's transport mechanisms, enabling selective passage into the brain and accumulation at the tumor site, thus overcoming the delivery barrier through the agent's inherent properties rather than external delivery devices
3Reliability
If surgery and radiotherapy are intensified to improve brain tumor treatment, then local control may be enhanced, but treatment options are restricted by tumor location and invasion into eloquent brain structures
Solution Approach 1:
The patent applies universality by introducing a chemotherapeutic agent that can treat brain tumors regardless of their specific location or extent of invasion into eloquent structures. Unlike surgery and radiotherapy which are constrained by anatomical considerations, the systemic chemotherapeutic agent ABT-751 can reach tumors throughout the brain through the bloodstream, providing a universal treatment approach that adapts to various tumor locations and surgical constraints
Solution Approach 2:
The patent substitutes the mechanical/physical approaches of surgery and radiotherapy with a chemical approach using ABT-751. Instead of mechanically removing or physically irradiating the tumor with location-dependent constraints, the chemical agent systematically targets tumor cells throughout the brain based on their biochemical characteristics, replacing the location-limited mechanical systems with a versatile chemical therapy that adapts to any tumor position
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ABT-751 sensitizes tumor cells to radiation, enhancing treatment efficacy while minimizing side effects, as demonstrated by improved survival and reduced tumor growth in murine models.
Implementation Method 1
ABT-751 can penetrate the brain (cross the blood-brain barrier) and in such a manner that it can selectively increase the radiation sensitivity of dividing tumor cells present in the brain
Implementation Method 2
delivering ionizing radiation (IR) to said subject
Data Source
AI summary
The current invention relates to a combination therapy comprising administering the antimitotic agent ABT-751 to a subject and delivering ionizing radiation to the same subject for the treatment of a brain tumor. Provided is for ABT-751 and ionizing radiation for use in such treatments.